Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CNTY-101 |
Trade Name | |
Synonyms | CNTY 101|CNTY101 |
Drug Descriptions |
CNTY-101 are iPSC-derived CAR-NK cells that have been engineered to express IL-15 and a chimeric antigen receptor (CAR) targeting CD19, which potentially results in tumor cell killing and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1729). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C187301 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CNTY-101 | CNTY-101 | 0 | 1 |